|Bid||0.00 x 4000|
|Ask||0.00 x 3200|
|Day's Range||3.5400 - 3.7700|
|52 Week Range||1.4600 - 7.2100|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2019 - Mar 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Despite diverse opinions about where the markets will head next, there are plenty of short-term penny stock trading opportunities into the new year.
The analysis showed promising activity in patients with FGFR2 gene fusion-expressing intrahepatic cholangiocarcinoma (iCCA) and also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
If you're interested in ArQule, Inc. (NASDAQ:ARQL), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
Premier Health Group (PHGRF) (PHGI), ArQule, Inc (ARQL), Amarin Corporation plc (AMRN), and AVEO Pharmaceuticals, Inc (AVEO) are 4 pharma stocks that may be worth keeping tabs on this week. Premier Health Group (PHGRF) (PHGI) is a company determined to improve the quality of care currently made available to consumers in the primary healthcare space. As an industry leader, the Company is focused on developing proprietary technologies to develop healthcare through a network of interconnected primary care clinics by way of artificial intelligence integration and telemedical advancements.
HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, ...
NEW YORK, Dec. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ArQule, Inc. (ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 24, 2018. The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB) and that meet certain eligibility criteria. The NBI is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF.
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego.
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
ArQule, Inc. (ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies (ARQ 531-101) that are being presented in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition on December 3, 2018 in San Diego. The C481S-mutation is a known resistance mechanism for first generation irreversible BTK inhibitors.
The big shareholder groups in ArQule Inc (NASDAQ:ARQL) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions Read More...
ArQule, Inc. (ARQL) today announced that it will present clinical data on the company’s BTK inhibitor, ARQ 531, in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 1 to 4, 2018 in San Diego. Updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies (ARQ 531-101) will be presented.
ArQule, Inc. (ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November 13 to 16, 2018 in Dublin, Ireland. The data presented highlight clinical data from ARQ 751-101, a Phase 1 study in adult patients with refractory and/or metastatic tumors that harbor AKT, PI3K or PTEN genetic alterations, and preclinical data on ARQ 751 in combination with other agents.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018, at 1:50pm ET at the Lotte New York Palace in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
Three poster presentations highlighting clinical data from ARQ 751-101 and preclinical data on ARQ 751 in combination with other agents
ArQule (ARQL) delivered earnings and revenue surprises of 16.67% and 104.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Burlington, Massachusetts-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...